ReviewAnnals of the Royal College of Surgeons of England2002
Studies using the anti-idiotypic monoclonal antibody 105AD7 in patients with primary and advanced colorectal cancer.
Review in Annals of the Royal College of Surgeons of England, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
- Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements.Frontiers in oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mortality from colorectal cancer has not changed appreciably in the last 30 years and new treatment avenues, such as immunotherapy, are being explored. 105AD7 is a form of active specific immunotherapy that aims to stimulate specific T-cells to target tumour specific antigens on colorectal cancer cells. Results indicate that the cancer vaccine 105AD7 is non-toxic and is capable of stimulating T-cells to target tumour specific antigens, become activated, and kill tumour cells by apoptosis. These immune responses have no effect on survival on a cohort of immunosuppressed patients with advanced disease, but results from a case-control study in patients with minimal residual disease suggest they may confer a slight survival advantage on patients receiving 105AD7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.